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A prospective, randomized, controlled trial was conducted to compare clinical outcomes in patients treated with an investigational
interspinous spacer (Superion) versus those treated with an FDA-approved spacer (X-STOP). One hundred sixty-six patients with
moderate lumbar spinal stenosis (LSS) unresponsive to conservative care were treated randomly with the Superion (n = 80)
or X-STOP (n = 86) interspinous spacer. Study subjects were followed through 6 months posttreatment. Zurich Claudication
Questionnaire (ZCQ) symptom severity scores improved 30% with Superion and 25% with X-STOP (both P<0.001). Similar
changes were noted in ZCQ physical function with improvements of 32% with Superion and 27% with X-STOP (both P<0.001).
Mean ZCQ patient satisfaction score ranged from 1.7 to 2.0 in both groups at all follow-up visits. The proportion of subjects that
achieved at least two of three ZCQ clinical success criteria at 6 months was 75% with Superion and 67% with X-STOP. Axial pain
decreased from 55 ±27mm at pretreatment to 22 ±26mm at 6 months in the Superion group (P<0.001) and from 54 ±29mm
to 32 ±31mm with X-STOP (P<0.001). Extremity pain decreased from 61 ±26mm at pretreatment to 18 ±27mm at 6 months
in the Superion group (P<0.001) and from 64 ±26mm to 22 ±30mm with X-STOP (P<0.001). Back function improved from
38 ± 13% to 21 ± 19% with Superion (P<0.001) and from 40 ± 13% to 25 ± 16% with X-STOP (P<0.001). Preliminary results
suggest that the Superion interspinous spacer and the X-STOP each eﬀectively alleviate pain and improve back function in patients
with moderate LSS who are unresponsive to conservative care.
1.Introduction
Lumbar spinal stenosis (LSS) is deﬁned as a narrowing of
the lumbar spinal canal and/or the intervertebral foramina
due to disc degeneration, bulging of the annulus, facet joint
hypertrophy, and/or thickening of the ligamentum ﬂavum
[1–3]. This progressive narrowing causes compression of
the neurovascular structures in the lumbar spine [4], which
manifests as intermittent neurologic symptoms (typically
low back and leg pain) with standing, ambulating, and trunk
extension. The annual incidence of LSS is 5 per 100,000 peo-
ple[5],and,inadultsovertheageof65years,LSSisthemost
common diagnosis in those who undergo spine surgery [6].
Nonsurgical management options such as activity mod-
iﬁcation, physical therapy, anti-inﬂammatory drugs, and
epidural steroid injections represent the standard of care
for initial treatment of mild claudication symptoms. The
long-term eﬀectiveness of these nonsurgical treatments is
limited, however, since none hinders the progression of the
disease [7–9]. This is supported by the fact that only 42% of
patientstreatedwithnonsurgicalmanagementforLSSreport
improvement in symptoms 10 years later [10].
Decompression surgery is often recommended to
patients with severe claudication symptoms who fail con-
servative care. In fact, surgery is performed on 21% of
patients within 3 years of an LSS diagnosis [11]. However,
the decision of if and when to operate varies widely among
physicians and is inﬂuenced by physician preference more
so than disease characteristics [12]. Consequently, many
patients may unnecessarily undergo invasive decompression2 Pain Research and Treatment
surgery (with or without fusion) for less-than-severe clau-
dication symptoms, a procedure associated with signiﬁcant
cost and morbidity [6, 13–15].
Implantation with a minimally invasive interspinous
spacer is an alternative treatment option for patients with
mild to moderate neurogenic intermittent claudication
secondary to LSS. An interspinous spacer is implanted
between contiguous spinous processes and acts to limit back
extension at the symptomatic level. The rationale for the
utility of these devices is that low back pain secondary to
LSS is often alleviated when patients ﬂex their lumbar spine
and is exacerbated with spinal extension [16]. Although use
of interspinous spacers dates back to the 1950s, frequent
dislodgements caused these devices to largely fall out of favor
until the last decade. Midterm results with newer devices
suggest that interspinous spacers improve patient symptoms
with rare reports of dislodgements [17, 18], although long-
term safety and eﬀectiveness are unknown [19]. The purpose
of this prospective, randomized, controlled trial was to com-
pare 6-month clinical outcomes in patients treated with an
investigational interspinous spacer versus those treated with
a Food and Drug Administration- (FDA-) approved spacer.
2. Methods
2.1. Clinical Trial Overview. This prospective, multicenter,
randomized, controlled, FDA-IDE trial enrolled 166 patients
(80 Superion, 86 X-STOP) from 22 sites in the United States
from September 2008 to December 2010. All research proce-
dures performed in this trial were in strict accordance with
a predeﬁned protocol that was approved by all researchers
and the institutional review board at each respective site.
The procedures used in this clinical trial were in accordance
with the recommendations of the Helsinki Declaration, and
each patient gave written, informed consent before surgery.
This trial is registered under ClinicalTrials.gov number
NCT00692276.
2.2. Subjects. Inclusion criteria for this trial included (a)
age ≥45 years, (b) persistent leg, buttock, or groin pain,
with or without back pain, which was relieved by lum-
bar ﬂexion, (c) symptomatic and undergoing unsuccessful
conservative treatment for at least 6 months, (d) diagnosis
of moderate LSS, deﬁned as 25% to 50% reduction in
lateral/centralforamendiametercomparedtoadjacentlevels,
and radiographic evidence of thecal sac and/or cauda equine
compression, nerve root impingement by either osseous
or nonosseous elements, and/or hypertrophic facets with
canal encroachment, (e) Zurich Claudication Questionnaire
Physical Function score ≥2.0, (f) able to sit for 50 minutes
without pain and to walk ≥50feet, and (g) able to provide
voluntary informed consent and to comply with the study
procedures.
Exclusion criteria included (a) LSS at three or more
levels, (b) concomitant surgical procedure required, (c)
grade II to V spondylolisthesis, (d) unremitting back pain
in any spinal position, (e) signiﬁcant lumbar instability,
deﬁned by ≥3mm translation or ≥5◦ angulation, (f) active
(a)
(b)
Figure 1: Superion interspinous spacer in situ. (a) A/P view, (b)
lateral view.
systemic disease that may aﬀect the welfare of the patient,
(g) vertebral osteoporosis or history of vertebral fracture,
(h) body mass index ≥40kg/m2, (i) previous lumbar spine
surgery, (j) pregnant or lactating female, and (k) any disease
or condition that, in the investigator’s opinion, may aﬀect
subject safety or confound trial outcomes.
2.3. Devices. Subjects were treated randomly with the
superion interspinous spacer system (Vertiﬂex, Inc., San
Clemente, CA, USA) or the X-STOP Interspinous Process
Decompression System (Medtronic, Inc., Sunnyvale, CA,
USA). The Superion device (Figures 1(a) and 1(b))i sa n
investigational device under study in this FDA-approved IDE
clinical trial, which is composed of titanium 6AI-4V ELI
alloy, a material commonly used in a variety of orthopedic
applications that conforms to ASTM standards for surgical
implants [20]. Five device sizes are available, ranging from
8 to 16mm, with the sizes corresponding to the amount
of desired distraction between the two spinous processes.
This single-piece, self-expanding implant is percutaneouslyPain Research and Treatment 3
delivered and deployed between the spinous processes of the
symptomatic vertebral levels.
The X-STOP device was approved for use in the United
States by the FDA in November 2005 and served as the
control device in this trial. The X-STOP device has been
described in detail elsewhere [21].
2.4. Pretreatment Procedures. Baseline assessments included
a complete physical examination, medical history, and study
eligibility based on the inclusion/exclusion criteria. Prepro-
cedural radiographic assessments included X-rays (standing
A/P, lateral lumbar, ﬂexion/extension lateral lumbar) and
magnetic resonance imaging or computed tomography of
the lumbar spine. The Zurich Claudication Questionnaire
(ZCQ) was utilized to assess patient-reported measures of
symptom severity, physical function, and patient satisfaction
[22]. Extremity and axial pain severity were measured
with a 100mm visual analogue scale. Degree of back-
speciﬁc functional disability was assessed with the Oswestry
Disability Index (ODI) (version 2) on a 0 to 100% scale [23].
2.5. Treatment. Despite minor diﬀerences in the surgical
technique for insertion of these devices, the procedures
are quite similar and are collectively described hereafter.
Subjects were laid prone on a radiolucent table with the
lumbar spine in a neutral or slightly ﬂexed position. Under
ﬂuoroscopic guidance or direct visualization, the surgical
level was identiﬁed and a midline incision was made
(Superion: 24 ± 11mm, X-STOP: 54 ± 21mm, P<0.001).
The supraspinous ligament was longitudinally dissected at
the symptomatic level and then dilated to ensure adequate
room to maneuver within the interspinous space. A cannula
wasinsertedoverthedilatorandproperalignmentanddepth
were ensured before dilator removal. Next, an interspinous
gauge was inserted through the cannula to determine proper
implant size selection, and ﬁnal midline positioning was
conﬁrmed under ﬂuoroscopy. The appropriately sized spacer
wasdeliveredthroughthecannulausingadeviceinserterthat
loaded, inserted into the interspinous space via the cannula,
and deployed the implant. Proper device placement was
conﬁrmedwithﬂuoroscopy.Finally,theinserterandcannula
were removed, and the incision was sutured in a standard
fashion. Proper postoperative placement of the Superion
deviceisillustratedradiographicallyinFigures2(a)and2(b).
2.6. Followup. Postoperatively, subjects were followed
through discharge and returned for visits at 6 weeks, 3
months, and 6 months. Radiographic evaluations included
standing A/P, lateral lumbar, and ﬂexion/extension lateral
lumbar (the latter was not performed at discharge) X-rays.
The ZCQ, extremity and axial pain severity, and back-
speciﬁc functional disability were assessed at 6 weeks,
3 months, and 6 months. The FDA-mandated primary
endpoint of this IDE clinical trial is 2 years, with postmarket
surveillance scheduled for 10 years.
2.7. Sample Size. The sample size for this noninferiority trial
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Figure 2: (a) A/P and (b) lateral radiographic image showing a
properly placed Superion Interspinous Spacer.
62.5% with the Superion device, a 60% success rate with the
X-STOP device, 90% statistical power, and a noninferiority
margin of 10%. Based on these assumptions, 300 to 600
total subjects (depending on enrollment time) were required
using a Bayesian adaptive approach. This paper describes the
preliminaryoutcomesoftheﬁrst166subjectsenrolledinthis
clinical trial.
2.8. Randomization and Blinding. Randomization was ach-
ieved by using a computer-generated master randomization
list of treatment assignments using a 1:1 allocation. Sites
utilized a web-based system to obtain randomization assign-
ment before each subject was enrolled. Treatments were
not concealed to investigators, outcome assessors, or trial
participants.
2.9. Data Analysis. Data were analyzed using Predictive Ana-
lytics Software (v. 18, SPSS, Inc., Chicago, IL). Continuous
data were reported as mean ± SD and categorical data
were reported as frequencies and percentages. Longitudinal4 Pain Research and Treatment
Randomized (n = 185)
Allocated to (n = 95) Allocated to S uperion (n = 90)
Received allocated intervention (n = 86) Received allocated intervention (n = 80)
Returned for
• Not meeting inclusion criteria (n = 6) • Not meeting inclusion criteria (n = 6)
• Declined to participate (n = 4)
• Awaiting visit (n = 45)
•
• Declined to participate (n = 1)
• Other reasons (n = 2)






Lost to followup (n = 0)
followup (n = 30)
Lost to followup (n = 0)
n = 35) Returned for 6-month followup (
Figure 3: Patient ﬂow diagram.





Age, mean ± SD,y 67 ± 96 7 ± 11
Male, n (%) 48 (60) 57 (66)
Body mass index, mean ± SD, kg/m2 30 ± 53 0 ± 5
Tobacco use, n( %)
None 34 (43) 41 (48)
Previous use 35 (44) 34 (40)
Current use 11 (14) 11 (13)
Axial pain severity score, mean ± SD, mm 55 ± 27 54 ± 29
Extremity pain severity score, mean ± SD, mm 61 ± 26 64 ± 26
Oswestry disability index, mean ± SD, % 38 ± 13 40 ± 13
changes in clinical outcomes were assessed with two-way
(time-by-treatment) repeated measures analysis of variance.
Area under the curve (AUC) was calculated for pain severity
and back function scores according to the methodology of
Matthews et al. [24]. Brieﬂy, this analysis uses all responses
of each subject to calculate a single number that summarizes
the response curve, after accounting for diﬀerential followup
intervals among subjects. Clinical success was deﬁned as
a ≥0.5 point improvement in ZCQ symptom severity and
physical function [22], ZCQ patient satisfaction score ≤2.5
[22], ≥20mm improvement in pain scores [25, 26]a n d
a ≥15 percentage point improvement in ODI [25, 27],
respectively.
3. Results
3.1. Subject Flow. A total of 185 subjects were randomized
in this clinical trial—90 to Superion and 95 to X-STOP
(Figure 3). Approximately 10% of randomized subjects were
withdrawn from the study before treatment due to not
meeting inclusion criteria during this period (n = 12),






General 68 (85) 79 (92)
Conscious sedation 12 (15) 7 (8)
Local 7(9) 4 (5)
Number of devices, n (%)
One 40 (50) 38 (44)
Two 40 (50) 48 (56)
Device size, n (%)
6mm NA 2 (2)
8mm 1 (1) 5 (4)
10mm 15 (12) 38 (28)
12mm 32 (27) 51 (38)
14mm 63 (52) 34 (25)
16mm 9 (8) NA
NR 0 (—) 4 (3)
Procedure time, median, mins 55 45
Procedural blood loss, median, cc 10 25
∗The sum of percentages is greater than 100% because more than one
anesthesia type was used in some patients. NR, not reported. NA, not
applicable.
declining to participate (n = 5), or other reasons (n = 2).
Ultimately, 80 subjects were treated with the Superion device
and86weretreatedwithX-STOP.Atthetimeofthisanalysis,
66 subjects (36 Superion, 30 X-STOP) had passed the 6-
month followup visit window.
3.2. Subject Characteristics. Baseline subject characteristics
(Table 1), device utilization, procedure time, and procedural







































weeks months months pretreatment
Figure 4: Improvement in ZCQ symptom severity scores through 6
months posttreatment. Values are mean ± 95% CI.
3.3. Zurich Claudication Questionnaire. ZCQ symptom
severity scores improved 30% with Superion and 25% with
X-STOP through 6 months (both P<0.001) (Figure 4).
Similar changes were noted in ZCQ physical function with
improvements of 32% with Superion and 27% with X-STOP
through 6 months (both P<0.001) (Figure 5). The mean
ZCQ patient satisfaction score ranged from 1.7 to 2.0 in both
groups at all followup visits (Figure 6). The proportion of
subjects who achieved ZCQ clinical success with Superion
and X-STOP was 75% and 53% for symptom severity, 64%
and 63% for physical function, and 78% and 93% for patient
satisfaction. The proportion of subjects that achieved at least
two of three ZCQ clinical success criteria at 6 months was
75% with Superion and 67% with X-STOP (Figure 7).
3.4. Axial Pain Severity. Axial pain decreased from 55 ±
27mm at pretreatment to 22 ± 26mm at 6 months in
the Superion group, which represented a 70% median
improvement compared to pretreatment values (P<0.001).
Subjects treated with the X-STOP device realized axial pain
median improvements of 64% (P<0.001), from 54±29mm
at pretreatment to 32 ± 31mm at 6 months (Figure 8). Axial
pain severity AUC across the entire range of subject followup
was29±21mmforSuperionand37±22mmforX-STOP.At
6monthsposttreatment,60%(21of35)ofSuperionsubjects
and 50% (15 of 30) of X-STOP subjects achieved axial pain
clinical success (Figure 9). A strong positive relationship
was noted between pretreatment axial pain severity and
magnitude of improvement following interspinous spacer
treatment in both groups (Figures 10(a) and 10(b)).
3.5. Extremity Pain Severity. Both treatment groups demon-






































weeks months months pretreatment
Figure 5: Improvement in ZCQ physical function scores through 6









































weeks months months pretreatment
Figure 6: ZCQ patient satisfaction scores through 6 months
posttreatment. Values are mean ± 95% CI.
extremity pain severity through 6 months posttreatment.
Superion subjects improved from a score of 61 ± 26mm at
pretreatment to 18 ± 27mm at 6 months, a 93% median
decrease. Subjects treated with the X-STOP device improved
from64±26mmatpretreatmentto22±30mmat6months,
an 81% median decrease (Figure 11). The extremity pain
severity AUC across the entire range of subject followup was
31 ±23mm for Superion versus 34 ±21mm for X-STOP. At





























































Figure 7: Overall ZCQ success rates through 6 months posttreat-



































weeks months months pretreatment
Figure 8: Improvement in axial pain severity through 6 months
posttreatment. Values are mean ± 95% CI mm.
and 60% (18 of 30) of X-STOP subjects achieved extremity
pain clinical success (Figure 12). A strong positive relation-
ship was noted between pretreatment extremity pain severity
and magnitude of improvement following interspinous
spacer treatment in both groups (Figures 13(a) and 13(b)).
3.6. Back-Speciﬁc Functional Impairment. Back function



























































































weeks months months posttreatment
Figure 9:Axialpainseverityclinicalsuccessratesthrough6months
posttreatment. Clinical success deﬁned as a ≥20mm improvement
from pretreatment.
posttreatment with the Superion device (38 ± 13% to 21 ±
19%) while improvements were 38% (40 ± 13% to 25 ±
16%) with X-STOP (P<0.001) (Figure 14). The back
function AUC across the entire range of subject followup
was 26 ± 14% for Superion versus 29 ± 14% for X-STOP.
Back function clinical success was achieved in 47% (17
of 36) with Superion and 37% (11 of 30) with X-STOP
(Figure15).Norelationshipwasnotedbetweenpretreatment
back function and magnitude of improvement following
interspinous spacer treatment in either group (Figures 16(a)
and 16(b)).
3.7. Complications. Device-related complications were note
in 7 patients per treatment group through 6 months
followup. In patients treated with the Superion device, 4
explants were performed between 1 and 4 months posttreat-
mentduetopersistentpain.Tworevisionswereperformed—
aforaminotomyat4monthsandaleft-sidedecompressionat
5 months with the Superion device left in situ. Spinal process
fracture was noted in one subject.
In patients treated with the X-STOP, two explants were
performed following device dislodgement at 1 month and
evidence of lumbosacral disc herniation at 4 months, respec-
tively. Spinal process fracture was noted in three subjects,
wound infection requiring readmission in one subject, and
a nerve root block for persistent pain at 4 months.
4. Discussion
Short-term clinical outcomes following implantation with
the Superion interspinous spacer system demonstrate ame-
lioration of low back and leg pain and improvements in
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0 > gain < 20
16.7%
52.1%
20 ≥ gain ≤ 100
31.3%
≤0
VAS back pain pretreatment value
(b)
Figure 10: Relationship of pretreatment axial pain severity with
absolute axial pain improvement at 6 months. (a) Superion, (b)
X-STOP. Data are reported in mm and include values from
pretreatment and from the ﬁnal subject followup visit at or beyond
3 months. The horizontal line represents the absolute change
threshold(20mm)forclinicalsuccess.Subjectsonorabovethisline
achievedclinicalsuccess.Thediagonallinerepresentsthemaximum
achievable absolute improvement based on the pretreatment value.
conservative treatments. The Superion device is a promising
therapeutic option in patients with moderate LSS with 6-
month clinical outcomes similar to those achieved with the
FDA-approved X-STOP device.
The clinical outcomes with the Superion device in this
clinical trial are comparable to those reported in the study
of Bini and colleagues who reported 1-year outcomes of
52 patients treated with the Superion device for moderate
LSS [28]. In that study, axial pain severity improved from
6.9 ± 1.1 at pretreatment to 3.4 ± 1.5a t1y e a r ,w h i c h
represented a 49% improvement (P<0.001). Extremity pain
severity similarly decreased from 6.6 ± 1.4 at pretreatment
to 2.8 ± 1.5 at 1 year, reﬂecting a 53% overall improvement
(P<0.001). Back function improved from 60 ± 8% at
pretreatment to 21 ± 14% at 1 year, representing a 64%
(P<0.001) improvement. For comparison, median percent



































weeks months months posttreatment pretreatment
Figure 11: Improvement in extremity pain severity through 6




















































































weeks months months posttreatment
Figure 12: Extremity pain severity clinical success rates through
6 months posttreatment. Clinical success deﬁned as a ≥20mm
improvement from pretreatment.
Superion device in the current trial were 70%, 93%, and
48% for axial pain, extremity pain, and back function,
respectively.
Despite signiﬁcant pain relief following implantation
with the Superion device, the mode of action with inter-
spinous spacersremainscontroversial.Potentialmechanisms
include widening of the lumbar spinal canal and increases
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VAS leg pain pretreatment value
(b)
Figure 13: Relationship of pretreatment extremity pain severity
with absolute extremity pain improvement at 6 months. (a)
Superion, (b) X-STOP. Data are reported in mm and include
values from pretreatment and from the ﬁnal subject followup
visit at or beyond 3 months. The horizontal line represents the
absolute change threshold (20mm) for clinical success. Subjects
on or above this line achieved clinical success. The diagonal line
represents the maximum achievable absolute improvement based
on the pretreatment value.
in intervertebral mobility although these have not been
reliably demonstrated. A cadaver study demonstrated that
implantation of the Superion device prevents supraphysio-
logical motion at the symptomatic level and has no adverse
impact on the local anatomy [29]. However, given the
weak relationship between radiographic ﬁndings and patient
symptoms in LSS, the clinical importance of this ﬁnding is
unknown.
A limitation of this clinical trial was the relatively short-
term followup period. Subjects in this trial will, however,
continue to be followed through 10 years posttreatment.
In addition, these preliminary results should be interpreted
with caution since total enrollment is anticipated to exceed
300 subjects. Blinding was not utilized in this trial and,
therefore,thepotentialforascertainmentbiasshouldbecon-










































Figure 14: Improvement in back function through 6 months
















































































Figure 15: Back function clinical success rates through 6 months
posttreatment. Clinical success deﬁned as a ≥15 percentage point
improvement from pretreatment.
only for patients that meet strict clinical and radiographic
criteria. Finally, we report no radiographic range of motion
data and, therefore, cannot comment on the mechanism of
improvement observed in these patients.
In conclusion, the Superion and X-STOP interspinous
spacers eﬀectively ameliorate pain and improve back func-
tion through 6 months in carefully selected patients with
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ODI back function pretreatment value
(b)
Figure 16: Relationship of pretreatment back function with
absolute back function improvement at 6 months. (a) Superion, (b)
X-STOP. Data are reported as percentages and include values from
pretreatment and from the ﬁnal subject followup visit at or beyond
3 months. The horizontal line represents the absolute change
threshold (15 percentage points) for clinical success. Subjects on
or above this line achieved clinical success. The diagonal line
represents the maximum achievable absolute improvement based
on the pretreatment value.
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